The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. - Wikidata - wikimedia - TriplyDB

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

http://www.wikidata.org/entity/Q35876204

about

Oncolytic virus therapy: A new era of cancer treatment at dawn Progress in systemic therapy of advanced hepatocellular carcinoma Viruses as nanomedicine for cancer Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1 Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses.Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Preferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude mice.CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice.Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.Oncolytic Poxviruses.The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy.Gene and cell therapy for pancreatic cancer.First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity Oncolytic virotherapy for ovarian cancer.Features of the Antitumor Effect of Vaccinia Virus Lister Strain Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1 Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer A rationally designed A34R mutant oncolytic poxvirus: improved efficacy in peritoneal carcinomatosis.Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer.Oncolytic myxoma virus: the path to clinic Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition.Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8⁺ T Cells that Protect Against Subcutaneous B16-OVA Melanoma.A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1.Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Oncolytic vaccines.Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm.Viral gene therapy for head and neck cancer.Treatment of Liver Cancer.Oncolytic viruses: a new class of immunotherapy drugs.Fighting Cancer with Mathematics and Viruses.

P2860

Q26739714-0BB43C03-E750-40D9-A694-BBC6C2EBF29C Q26740217-3BC53E72-BBC7-48C3-8D74-8252437691F0 Q27690636-163A5BE1-8015-4505-9C8E-C67C5EF6C755 Q28071998-3A12F432-FAC2-4E44-BED3-0930B17DB842 Q33579883-7787358A-12F2-422B-8273-7A607257FFE3 Q33606166-1CF60349-7047-40A3-BE63-C077E712F049 Q34327051-792B5ED2-51C1-4835-A36F-18957E1A0293 Q34438608-7995FDCD-60C4-49D1-B56A-FC917A549C01 Q34476278-9508AA3B-FDF9-463A-B649-61209309C564 Q35110264-3BC704BF-1175-4897-9D22-230327B1E5CF Q35153121-A5897205-73D8-4DEB-B1C0-F974983926BF Q35176800-3AB4C6E3-5125-4A59-AEB0-B2E111D5B276 Q35234349-1B9D4A54-F767-4E13-883B-5FBFE37CACDF Q35417571-01C20EDB-8F41-414F-B96D-1380CD8994E2 Q35541787-E26BE511-523B-467F-B8F9-7E9477B454D6 Q35591435-859C17B2-5444-4194-A030-F70E47D8D514 Q35597082-62AA6EEA-0CB5-4E2D-B483-D28F9904A7C2 Q36507293-8806BBAF-2F6F-49B9-AEFE-01B64A76AF59 Q36582828-742D22E7-4056-42B9-B8B6-863359BC2544 Q36664229-858D93E1-337D-4D9E-9282-EE876E3C20BD Q36756690-030E2C9C-CFC2-4496-B79B-C01E39417F93 Q36757045-D4A0E0AC-AFB5-4BDA-9DC5-1897B12E954B Q36883833-F4FF786A-4552-4FA8-A712-1676EFDE7CA4 Q37031733-99FC7387-512A-425D-AE0E-F59F51B45FFA Q37086063-F0805422-974B-4002-A2C9-D8F18B837257 Q37126088-026B852C-6FD6-43FA-AEF0-12A86407D6BD Q37158473-E893EAE3-AF66-40EC-8743-D93520B20B55 Q37256174-B708BCB8-0D3F-4AC7-9925-7F13BA769F8A Q37380398-B1B8113C-8936-4A05-ACDE-5D5BFE136DD6 Q37539236-277C24C0-BB8D-471E-822A-845D2514722B Q37565501-8D64C6AC-0B51-4733-A016-5A8453FBF513 Q37687542-3AADDF99-59DF-44B7-BA5A-9BECC4FC9A89 Q38008023-4A153EFD-B018-497A-8071-CE9E08367FC5 Q38025696-708D30C6-3338-4CAD-B400-718C97B9F2B2 Q38152474-BF1AE040-6285-4818-8F51-B75F98799040 Q38264652-A0B1696C-0642-43E1-8ACA-9B4DED140161 Q38381706-B2471A6E-06B4-4503-9341-4775398BFCB2 Q38549768-2AABD154-D248-4D72-9E11-8A17914368F7 Q38577450-02C432A1-024E-43EF-9A2D-8BC1B04C7B56 Q38612646-1E39D20F-2EFB-44E6-8BA2-2F33D5C22F38

P2860

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

http://www.wikidata.org/entity/Q35876204

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

The oncolytic poxvirus JX-594 ...... commonly activated in cancers.

@ast

The oncolytic poxvirus JX-594 ...... commonly activated in cancers.

@en

type

label

The oncolytic poxvirus JX-594 ...... commonly activated in cancers.

@ast

The oncolytic poxvirus JX-594 ...... commonly activated in cancers.

@en

prefLabel

The oncolytic poxvirus JX-594 ...... commonly activated in cancers.

@ast

The oncolytic poxvirus JX-594 ...... commonly activated in cancers.

@en

P1433

Q35876204-0BD168DF-55F2-495D-96A4-86CB0438CC4A

P1476

Q35876204-C9C9F9E8-12C2-4DD7-8776-11B236A325E6

P2093

Q35876204-208E6F63-DC7B-4471-86DE-F7C946FE3B61

Q35876204-28DBE408-7224-4FDB-9EFB-3031B3357EBC

Q35876204-3159FBD6-E02C-4E76-9F1A-A4E5AF3A0DB8

Q35876204-357B7A74-6BD5-4319-817B-AF6F7BF13A6B

Q35876204-35F426B8-C873-4B66-9DF7-434E8A5A8002

Q35876204-403904C0-41A7-41B2-A63E-C4E2C5BBCE3F

Q35876204-450BB09F-E7F6-4E93-8DA2-E1E1830B55C0

Q35876204-47B99A5F-6A4C-4885-8093-80CDF5E22443

Q35876204-537D91A6-E28B-415C-919B-4E50B53B630B

Q35876204-53E9D9A3-393B-4EF2-9CD5-444CB78140D1

P2860

Q35876204-0059D390-31F0-44DC-A186-34979D28ECD2

Q35876204-00951A45-5905-402B-B071-CA0F9647CECC

Q35876204-0318ACE7-6F9E-4B62-87A2-776411C90180

Q35876204-109D5A66-4371-470E-BE05-92957231DDFE

Q35876204-199620F1-7195-4C0D-AC73-7558B3916DD9

Q35876204-1EE3CD0A-1B10-4630-84A8-850A441D9D82

Q35876204-25B7C28B-CF28-4387-8795-6E373AA78B77

Q35876204-275B37F7-B04A-4E4E-806E-35BD60F5F86D

Q35876204-292225CE-BDF7-4A64-AC05-82BD529C40C8

Q35876204-31C6EFE9-F221-46DC-B5AF-97EED2B8D84B

P304

Q35876204-DD1CED14-EB0E-4ABD-BF0C-1F383F201B91

P31

Q35876204-FF2EDA6A-B696-402A-9252-9D6DDE4B0E95

P356

Q35876204-6BCA24D6-43FE-45B6-A1F9-27D59373EA4E

P433

Q35876204-4792103A-FACB-4DDE-AE9F-68FE86676FEF

P478

Q35876204-5FCC424A-8EC6-4C2F-98A1-F9555ED72FE8

P50

Q35876204-1FA32E41-CBA7-42B2-91FF-3EA479569A2E

P577

Q35876204-FDD908FB-773F-4E47-AC1A-9A866F693278

P5875

Q35876204-23847CB6-796A-4129-9C7B-4DB5E280F035

P698

Q35876204-B264EB55-E44F-4581-AD3C-0816B7367535

P921

Q35876204-23F5F7BA-0FFF-4E70-A7AE-4E476865E54F

P932

Q35876204-6CB2A516-5E53-4C4F-A5AD-F2E9921ACCB9

P356

P1433

Molecular Therapy

P1476

The oncolytic poxvirus JX-594 ...... commonly activated in cancers.

@en

P2093

Barbara C Vanderhyden

http://www.w3.org/2001/XMLSchema#string

Carolina Ilkow

http://www.w3.org/2001/XMLSchema#string

Caroline J Breitbach

http://www.w3.org/2001/XMLSchema#string

Chris Storbeck

http://www.w3.org/2001/XMLSchema#string

David H Kirn

http://www.w3.org/2001/XMLSchema#string

Fabrice Le Boeuf

http://www.w3.org/2001/XMLSchema#string

Femina Kanji

http://www.w3.org/2001/XMLSchema#string

Francois Paradis

http://www.w3.org/2001/XMLSchema#string

Jean-Simon Diallo

http://www.w3.org/2001/XMLSchema#string

Jiahu Wang

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Identification and expansion of human colon-cancer-initiating cells

Identification and expansion of the tumorigenic lung cancer stem cell population

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus

Pancreatic cancer

Mutations of the BRAF gene in benign and malignant melanocytic lesions.

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction.

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.

P304

749-758

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2011.276

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232756635

http://www.w3.org/2001/XMLSchema#string

P698

22186794

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

3321594

http://www.w3.org/2001/XMLSchema#string